Table 4.

Stratification Analysis of SCCHN Risk Associated with pre-miRNA hsa-146a,hsa-196a, hsa-149 and hsa499 Combined Genotypes

	No. of cases (%)		No. of controls (%)		Adjusted OR (95% CI)*
Characteristic	Ref. Group	Risk Group	Ref. Group	Risk Group	Ref. Group	Risk Group
	(0–1)	(2–4)	(0–1)	(2–4)	(0–1)	(2–4)
Age (years)
≤ 57	78 (13.2)	513 (86.8)	100 (17.0)	488 (83.0)	Ref.	1.34 (1.00–1.87)
> 57	93 (18.0)	425 (82.0)	105 (19.4)	437 (80.6)	Ref.	1.17 (0.84–1.62)
Sex
Male	128 (15.3)	709 (84.7)	160 (18.6)	700 (81.4)	Ref.	1.29 (1.00–1.69)
Female	43 (15.8)	229 (84.2)	45 (16.7)	225 (83.3)	Ref.	1.06 (0.65–1.73)
Smoking status
Never	43 (14.0)	264 (86.0)	103 (18.6)	450 (81.4)	Ref.	1.41 (1.00–2.08)
Ever	128 (16.0)	674 (84.0)	102 (17.7)	475 (82.3)	Ref.	1.16 (0.86–1.57)
Alcohol use
Never	42 (13.9)	261 (86.1)	89 (18.0)	405 (82.0)	Ref.	1.36 (0.91–2.04)
Ever	129 (16.0)	677 (84.0)	116 (18.2)	520 (81.8)	Ref.	1.18 (0.88–1.57)
Tumor site
Oral cavity	53 (16.3)	273 (83.7)	205 (18.1)	925 (81.9)	Ref.	1.06 (0.75–1.51)
Oropharynx	83 (14.7)	483 (85.3)	205 (18.1)	925 (81.9)	Ref.	1.32 (1.00–1.76)
Larynx/Hypopharynx	35 (16.1)	182 (83.9)	205 (18.1)	925 (81.9)	Ref.	1.12 (0.72–1.75)

^*Adjusted for age, sex, smoking status, and alcohol use in a logistic regression model.